Clinical Trial Update: Phase II Study of IRD (Ixazomib, Lenalidomide, Dexamethasone) Post Autologous Stem Cell Transplantation Followed by Maintenance Ixazomib or Lenalidomide for Multiple Myeloma [Phase 2]

View source ↗

Summary

Phase II study of IRD (ixazomib, lenalidomide, dexamethasone) after autologous stem cell transplantation in multiple myeloma, followed by maintenance with ixazo…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• DEXAMETHASONE (Dexamethasone)
• NINLARO (ixazomib)
• Revlimid (lenalidomide)

Snippet

Sponsor: Washington University School of Medicine | Conditions: Multiple Myeloma | Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2021-09-23